Recent Updates
-
Updated on: Dec 07, 2022
*NQF 0004 (Additional): Initiation and Engagement of Alcohol and Other Drug Dependence Treatment (a) Initiation, (b) Engagement
Measure: NQF 0004 (Additional Measure)
Measure Title: Initiation and Engagement of Alcohol and Other Drug Dependence Treatment: (a) Initiation, (b) Engagement
Measure Description: The percentage of adolescent and adult patients with a new episode of alcohol and other drug (AOD) dependence who initiate treatment through an inpatient AOD admission, outpatient visit, intensive outpatient encounter or partial hospitalization within 14 days of the diagnosis and who initiated treatment and who had two or more additional services with an AOD diagnosis within 30 days of the initiation visit.
-
Updated on: Dec 07, 2022
NQF 0032 (Additional): Cervical Cancer Screening
Measure: NQF 0032 (Additional Measure)
Measure Title: Cervical Cancer Screening
Measure Description: Percentage of women 21-64 years of age, whom received one or more Pap tests to screen for cervical cancer.
*REQUIRED FOR MEANINGFUL USE (MU) ADDITIONAL QM MEASURE: Click here to view Meaningful Use Criteria.
-
Updated on: Dec 07, 2022
NQF 0075 (Additional): Ischemic Vascular Disease (IVD): Complete Lipid Panel and LDL Control
Measure: NQF 0075 (Additional Measure)
Measure Title: Ischemic Vascular Disease (IVD): Complete Lipid Panel and LDL Control
Measurement Description: The percentage of patients 18 years of age and older who were discharged alive for acute myocardial infarction (AMI), coronary artery bypass graft (CABG) or percutaneous transluminal coronary angioplasty (PTCA) from January 1–November 1 of the year prior to the measurement year, or who had a diagnosis of ischemic vascular disease (IVD) during the measurement year and the year prior to the measurement year and who had a complete lipid profile performed during the measurement year and whose LDL-C was <100 mg/dL.
*REQUIRED FOR MEANINGFUL USE (MU): Click here to view the Meaningful Use Criteria.
-
Updated on: Dec 07, 2022
NQF 0055 (Additional) Diabetes: Eye Exam
Measure: NQF 0055 (Additional Measure)
Measure Title: Diabetes: Eye Exam
Measure Description: The percentage of patients 18–75 years of age with Diabetes (Type 1 or Type 2) whom had a retinal or dilated eye exam or a negative retinal exam (no evidence of retinopathy) by an eye care professional.
*REQUIRED FOR MEANINGFUL USE (MU) ADDITIONAL MEASURE: Click here to view the Meaningful Use Criteria.
-
Updated on: Dec 07, 2022
NQF 0012 (Additional): Prenatal Care - Screening for Human Immunodeficiency Virus (HIV)
Measure: NQF 0012 (Additional Measure)
Measure Title: Prenatal Care: Screening for Human Immunodeficiency Virus (HIV)
Measure Description: Percentage of patients, regardless of age, who gave birth during a 12-month period who were screened for HIV infection during the first or second prenatal visit.
-
Updated on: Dec 07, 2022
(DRAFT) *NQF 0033 (Additional): Chlamydia Screening for Women age 15-24
Measure: NQF 0033 (Additional Measure)
Measure Title: Chlamydia Screening for women
Measure Description: Percentage of women 15-24 years of age whom were identified as sexually active and whom had at least one test for chlamydia during the reporting period.
*REQUIRED FOR MEANINGFUL USE (MU) ADDITIONAL QM MEASURE: Click here to view Meaningful Use Criteria.
-
Updated on: Dec 07, 2022
NQF 0575 (Additional): Diabetes: Hemoglobin A1c Control (<8.0%)
Measure: NQF 00575 (Additional Measurement)
Measure Title: Diabetes: HbA1c Control (<8%)
Measure Description: The percentage of patients 18–75 years of age with diabetes (type 1 or type 2) whom had HbA1c <8.0%.
-
Updated on: Dec 07, 2022
NQF 0001 - (Additional) Asthma Assessment
Measure: NQF 0001 (Additional Measure)
Measure Title: Asthma Assessment
Measure Description: Percentage of patients aged 5 through 40 years with a diagnosis of asthma and who have been seen for at least 2 office visits, who were evaluated during at least one office visit within 12 months for the frequency (numeric) of daytime and nocturnal asthma symptoms.
-
Updated on: Dec 07, 2022
NQF 0387 - (Additional) Oncology Breast Cancer: Hormonal Therapy for Stage IC-IIIC Estrogen
Measure: NQF 0387 (Additional Measurement)
Measure Title: Oncology Breast Cancer: Hormonal Therapy for Stage IC-IIIC Estrogen
Measure Description: Oncology Breast Cancer: Hormonal Therapy for Stage IC-IIIC Estrogen Receptor/Progesterone Receptor (ER/PR) Positive Breast Cancer.
-
Updated on: Dec 07, 2022
NQF 0002 - (Additional) Appropriate Testing for Children with Pharyngitis
Measure: NQF 0002 (Additional Measure)
Measure Title: Appropriate Testing for Children with Pharyngitis
Measure Description: The percentage of children 2–18 years of age who were diagnosed with Pharyngitis, dispensed an antibiotic and received a group A streptococcus (strep) test for the episode.